Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,429 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Differential Binding of Sarilumab and Tocilizumab to IL-6Rα and Effects of Receptor Occupancy on Clinical Parameters.
Xu C, Rafique A, Potocky T, Paccaly A, Nolain P, Lu Q, Iglesias-Rodriguez M, St John G, Nivens MC, Kanamaluru V, Fairhurst J, Ishii T, Maldonado R, Choy E, Emery P. Xu C, et al. Among authors: emery p. J Clin Pharmacol. 2021 May;61(5):714-724. doi: 10.1002/jcph.1795. Epub 2021 Jan 26. J Clin Pharmacol. 2021. PMID: 33314148 Free article.
Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register.
Harrison MJ, Dixon WG, Watson KD, King Y, Groves R, Hyrich KL, Symmons DP; British Society for Rheumatology Biologics Register Control Centre Consortium; BSRBR. Harrison MJ, et al. Ann Rheum Dis. 2009 Feb;68(2):209-15. doi: 10.1136/ard.2007.087288. Epub 2008 Apr 2. Ann Rheum Dis. 2009. PMID: 18385277 Free PMC article.
IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial.
Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, Alecock E, Lee J, Kremer J. Emery P, et al. Ann Rheum Dis. 2008 Nov;67(11):1516-23. doi: 10.1136/ard.2008.092932. Epub 2008 Jul 14. Ann Rheum Dis. 2008. PMID: 18625622 Free PMC article. Clinical Trial.
No evidence of association between anti-tumor necrosis factor treatment and mortality in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Lunt M, Watson KD, Dixon WG; British Society for Rheumatology Biologics Register Control Centre Consortium; Symmons DP, Hyrich KL; British Society for Rheumatology Biologics Register. Lunt M, et al. Arthritis Rheum. 2010 Nov;62(11):3145-53. doi: 10.1002/art.27660. Arthritis Rheum. 2010. PMID: 20662063 Free PMC article.
Differential effects of infliximab on absolute circulating blood leucocyte counts of innate immune cells in early and late rheumatoid arthritis patients.
Coulthard LR, Geiler J, Mathews RJ, Church LD, Dickie LJ, Cooper DL, Wong C, Savic S, Bryer D, Buch MH, Emery P, Morgan AW, McDermott MF. Coulthard LR, et al. Among authors: emery p. Clin Exp Immunol. 2012 Oct;170(1):36-46. doi: 10.1111/j.1365-2249.2012.04626.x. Clin Exp Immunol. 2012. PMID: 22943199 Free PMC article. Clinical Trial.
Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions.
Smolen JS, Schoels MM, Nishimoto N, Breedveld FC, Burmester GR, Dougados M, Emery P, Ferraccioli G, Gabay C, Gibofsky A, Gomez-Reino JJ, Jones G, Kvien TK, Murakami M, Betteridge N, Bingham CO 3rd, Bykerk V, Choy EH, Combe B, Cutolo M, Graninger W, Lanas A, Martin-Mola E, Montecucco C, Ostergaard M, Pavelka K, Rubbert-Roth A, Sattar N, Scholte-Voshaar M, Tanaka Y, Trauner M, Valentini G, Winthrop KL, de Wit M, van der Heijde D. Smolen JS, et al. Among authors: emery p. Ann Rheum Dis. 2013 Apr;72(4):482-92. doi: 10.1136/annrheumdis-2012-202469. Epub 2012 Nov 21. Ann Rheum Dis. 2013. PMID: 23172750 Free PMC article.
Abatacept or tocilizumab after rituximab in rheumatoid arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapy.
Das S, Vital EM, Horton S, Bryer D, El-Sherbiny Y, Rawstron AC, Ponchel F, Emery P, Buch MH. Das S, et al. Among authors: emery p. Ann Rheum Dis. 2014 May;73(5):909-12. doi: 10.1136/annrheumdis-2013-204417. Epub 2014 Jan 2. Ann Rheum Dis. 2014. PMID: 24385201
1,429 results